Expression of secreted phospholipase A2-Group IIA correlates with prognosis of gastric adenocarcinoma

Abstract

Abstract. The present study investigated the expression of secretory phospholipase A2-Group IIA (sPLA2-II) in gastric adenocarcinoma, in order to evaluate the correlation between sPLA2-II expression, and the clinicopathological features and prognosis of patients with gastric adenocarcinoma. Between January 2007 and April 2010, data were collected from 65 patients (44 males, 21 females; age range, 30-79 years; mean 66.7 ± 10.7 years). All patients exhibited a pathologically confirmed diagnosis of gastric adenocarcinoma. Endoscopic biopsy specimens of normal gastric mucosa from 11 of these patients were used as controls. Patients were subsequently followed-up at 3-month intervals, and survival data were recorded until April 2010. Expression of sPLA2-II in 65 gastric adenocarcinoma and 11 normal gastric mucosa specimens was evaluated via immunohistochemistry. A semi-quantitative method, consisting of evaluation of staining percentage and intensity, was utilized for immunohistochemical scoring, and the receiver operating characteristic curve method was applied to select a cut-off score for high and low sPLA2-II expression. The value of 8 was selected as the cut-off score, with maximum sensitivity and specificity. High sPLA2-II expression was observed in stage III/IV cases (83.3%; 40/48) and poorly differentiated cells (94.1%; 32/34), while sPLA2-II expression levels were observed to be significantly lower in stage I/II cases (52.9%; 9/17) and well and moderately differentiated cells (54.8%; 17/31; P=0.021 and P<0.001, respectively). There were no significant correlations observed between sPLA2-II expression and any other clinicopathological parameters, including gender, age, tumor diameter and Helicobacter pylori infection. Patients exhibiting low sPLA2-II expression experienced significantly improved overall survival (OS) and disease-free survival (DFS), compared with those exhibiting high sPLA2-II expression (P=0.043 and P=0.035, respectively). Multivariate analysis confirmed that high sPLA2-II expression may be an independent prognostic factor for OS [relative risk, 2.849; 95% confidence interval (CI), 1.088-7.459; P= 0.033] and DFS (relative risk, 2.735; 95% CI, 1.104-6.776; P=0.030) in gastric adenocarcinoma. Therefore, sPLA2-II may be correlated with the histogenesis of gastric adenocarcinoma, and increased sPLA2-II expression may be an indicator of poor prognosis.

Potential Benefits of Jujube (Zizyphus Lotus L.) Bioactive Compounds for Nutrition and Health

“…These reports suggest that the extracts of this plant act as antiulcer agent by reducing gastric acidity and juice secretion. Helicobacter pylori is the most common bacterium that can survive in the highly acidic environment of the human stomach involving different digestive diseases such as peptic ulcer, dyspepsia (heartburn, acid indigestion, and nausea) [75, 76], the stomach cancer (adenocarcinoma) [77, 78], and MALT lymphoma [79]. Interestingly, the effect of methanol extract of Z. lotus (fruits) has been studied in vitro on 22 clinical strains of Helicobacter pylori , indicating that this plant has bactericidal effects on these clinical strains [21].…”

Sterically stabilized liposomes targeting P21 (RAC1) activated kinase‑1 and secreted phospholipase A₂ suppress prostate cancer growth and metastasis

“…These alterations ensure that SPRL is more responsive to cancers, that overexpress SPLA 2 , including prostate, breast, gastric, lung, and colon cancers ( 30 , 31 ). sPLA 2 cleave phospholipids at the sn-2 (a nucleophilic substitution in which the rate-determining step involves 2 components) bond of the glycerol backbone releasing fatty acid and lysophospholipids ( 31 – 35 ). Unlike other PLA 2 , sPLA 2 has a strong affinity for negatively charged phospholipid head groups, in particular, phosphatidylserine, phosphatidylglycerol, and phosphatidylethanolamine ( 17 , 36 ).…”

Context-dependent effect of sPLA2-IIA induced proliferation on murine hair follicle stem cells and human epithelial cancer

“…For instance, sPLA 2 -IIA is constitutively expressed in inflammatory diseases such as infections, septic shock, and rheumatoid arthritis. In addition, abnormal expression of sPLA 2 -IIA has also been reported in diverse human cancers [[11], [12], [13], [14],41,42]. However, the effect of sPLA 2 -IIA induced proliferation on ultimate fate of normal and tumour cells in a different cellular context remains to be investigated.…”

“…Secretory phospholipases are known to be involved in a wide range of physiological and pathophysiological conditions [10]. In fact, sPLA 2 -IIA modulate tumorigenesis of the prostate [11], colon [12], gastric adenocarcinoma [13], lung [14] and oesophageal cancers [15]. Besides, sPLA 2 also induces proliferation of astrocytoma and microglia cells [16,17], suggesting its ability to promote cellular proliferation in a wide range of normal and transformed tissue types.…”